Navigation Links
BioMS Medical announces its intention to renew a normal course issuer bid
Date:9/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.1% of the Company's issued and outstanding Common Shares.

The bid will commence September 8, 2008 and will expire September 7, 2009 or such earlier date as the Company may complete its purchases. The price at which the Company will purchase its shares will be the market price thereof at the time of acquisition. Purchases of Common Shares will be made in the open market through the facilities of the TSX. Any Common Shares acquired by the Company will be cancelled. The Company has 91,180,923 Common Shares issued and outstanding as of August 27, 2008. During the previous 12 months, the Company acquired 343,300 of its Common Shares at an average price of $3.37 per share by way of a normal course issuer bid. The average daily trading volume of the Common Shares on the TSX (exclusive of purchases under the Company's previous normal course issuer bid) for the period February 1, 2008 to July 31, 2008 was 78,945 shares. Daily purchases will be limited to 19,736 Common Shares, other than block purchase exceptions.

The Board of Directors of the Company believes that the market price of the Common Shares may not fully reflect the value of the Company's business and its future business prospects. As a result, the Board has concluded that the purchase and cancellation of the Common Shares may represent an appropriate and desirable use of the Company's funds and provide market stability.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commer
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... ... ... EDMONTON , March 16 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... , ...
... Mina Mar Group ( http://www.minamargroup.com/ ) as forefront representative of the company,s new expansive corporate interests. , ... , , ... ... ...
... it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of the filing of an,Abbreviated New Drug Application ("ANDA") ... ... , , ... ...
Cached Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 2DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 3DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 4DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 5DDS Technologies USA, Inc. (DDSU) Appoints Mina Mar Group as Its Corporate Advisor for a Merger 6Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Simplifying the process for forming compounds that can be ... plastics, has earned one University of Houston chemist a ... of chemistry in the College of Natural Sciences and ... mathematicians and economists in the United States and Canada ...
... productive as conventional systems" The answer is an unqualified, ... most of the time for corn and soybeans according ... Wisconsin-Madison and agricultural consulting firm AGSTAT in the March-April ... their answer on results from the Wisconsin Integrated Cropping ...
... biosensing nanodevice developed by Arizona State University researcher ... security checkpoints and revolutionize health screenings for diseases ... (MRSA). Even more incredible than the device ... worlds tiniest rotary motor: a biological engine measured ...
Cached Biology News:Simplifying manufacture of drugs, plastics earns UH chemist top honor 2Are organic crops as productive as conventional? 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Biology Products: